Genzyme OKs $2B buyback, mulls options for 3 units – The Associated Press
By Dr. Matthew Watson
 Reuters | Genzyme OKs $2B buyback, mulls options for 3 units The Associated Press Biotechnology company Genzyme Corp. said Thursday its board of directors approved a $2 billion stock buyback program and the company said it will explore ... Genzyme to buy back $2 billion in stockBoston Globe Icahn Tries to Replace 4 Directors at GenzymeNew York Times (blog) Special Report: Inside the battle for Genzyme's futureReuters Bizjournals.com -TheStreet.com -MarketWatch (press release) all 169 news articles » |
Uncategorized
Comments Off on Genzyme OKs $2B buyback, mulls options for 3 units – The Associated Press |
May 7th, 2010
This author published 5472 posts in this site.Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research